2024

1. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

   Journal of Neurology, Vol. 271, Núm. 9, pp. 5813-5824

2. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

   Blood, Vol. 143, Núm. 18, pp. 1807-1815

3. Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale

   Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2

4. Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study

   Clinical Microbiology and Infection, Vol. 30, Núm. 8, pp. 1035-1041

5. Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial

   eClinicalMedicine, Vol. 72

6. Biosimilars and access to biologic therapy in immune-mediated diseases

   Expert Opinion on Biological Therapy, Vol. 24, Núm. 7, pp. 647-653

7. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

   Multiple Sclerosis and Related Disorders, Vol. 90

8. Clinical impact of remote heart failure management using the multiparameter ICD HeartLogic alert

   Revista Espanola de Cardiologia

9. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

   Journal of medical economics, Vol. 27, Núm. 1, pp. 109-125

10. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence , Vol. 18, pp. 1163-1171

11. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

12. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

    The Lancet Child and Adolescent Health, Vol. 8, Núm. 5, pp. 348-357

13. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

14. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

    Infection

15. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

16. Incident comorbidities in patients with chronic hypoparathyroidism after thyroidectomy: a multicenter nationwide study

    Frontiers in Endocrinology, Vol. 15

17. Increased Severity of Mycoplasma pneumoniae Infections in Spanish Children

    Pediatric Infectious Disease Journal

18. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

19. Longitudinal transcriptional immune profiles and persistent wheezing in moderate-to-late preterm infants

    Pediatric Allergy and Immunology, Vol. 35, Núm. 10

20. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

    PLOS Digital Health, Vol. 3, Núm. 7